Correction: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion

  • Erika Hamilton1,

    Affiliated with

    • Kimberly Blackwell1,

      Affiliated with

      • Amy C Hobeika2,

        Affiliated with

        • Timothy M Clay3,

          Affiliated with

          • Gloria Broadwater4,

            Affiliated with

            • Xiu-Rong Ren5,

              Affiliated with

              • Wei Chen5,

                Affiliated with

                • Henry Castro3,

                  Affiliated with

                  • Frederic Lehmann3,

                    Affiliated with

                    • Neil Spector1,

                      Affiliated with

                      • Junping Wei6,

                        Affiliated with

                        • Takuya Osada6,

                          Affiliated with

                          • H Kim Lyerly2 and

                            Affiliated with

                            • Michael A Morse1Email author

                              Affiliated with

                              Journal of Translational Medicine201311:82

                              DOI: 10.1186/1479-5876-11-82

                              Received: 26 March 2013

                              Accepted: 26 March 2013

                              Published: 27 March 2013

                              Corrections

                              In our original manuscript [1], the corresponding author, Michael A Morse, was missed from the authors’ list. Therefore the correct author list should be:

                              Erika Hamilton, Kimberly Blackwell, Amy C Hobeika, Timothy M Clay, Gloria Broadwater, Xiu-Rong Ren, Wei Chen, Henry Castro, Frederic Lehmann, Neil Spector, Junping Wei, Takuya Osada, H Kim Lyerly and Michael A Morse.

                              Also the title of our original manuscript ‘Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion’ is also incorrect. The title should read:‘Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition’.

                              Journal of Translational Medicine regret any inconvenience that this inaccuracy might have caused.

                              Authors’ contribution

                              All authors read and approved the final manuscript.

                              Declarations

                              Authors’ Affiliations

                              (1)
                              Department of Medicine, Division of Medical Oncology, Duke University Medical Center
                              (2)
                              Department of Surgery, Division of General Surgery, Duke University Medical Center
                              (3)
                              GlaxoSmithKline Biologicals
                              (4)
                              Cancer Statistical Center, Duke Cancer Institute
                              (5)
                              Department of Medicine, Division of Gastroenterology, Duke University Medical Center
                              (6)
                              Department of Surgery, Division of Surgical Sciences, Duke University Medical Center

                              References

                              1. Hamilton : Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion. J Transl Med 2012, 10:28.PubMedView Article

                              Copyright

                              © Hamilton et al.; licensee BioMed Central Ltd. 2013

                              This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                              Advertisement